Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Influenza A (H1N1) 2009 Pandemic Monovalent Vaccine (Without Adjuvant)** is an inactivated, split-virion, monovalent influenza vaccine indicated for active immunization against the 2009 pandemic H1N1 influenza strain. The vaccine contains 15 µg hemagglutinin per 0.5 mL dose from the A/California/7/2009 (H1N1)v-like strain and is produced by propagating virus in embryonated hens' eggs, inactivating with ultraviolet and formaldehyde, and disrupting with sodium deoxycholate. Designed specifically for pandemic response, it does not contain an adjuvant and is distinct from seasonal influenza vaccines. Its mechanism is to induce immunity through presentation of influenza viral antigens to elicit a humoral immune response (antibody-mediated protection) against the H1N1 virus[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on influenza a (h1n1) 2009 pandemic monovalent vaccine (without adjuvant).